Comorbid Conditions of Ehlers–Danlos Syndromes and Vulvodynia: A Latent Class Analysis ,
Abstract
Purpose: Having an Ehlers-Danlos syndrome (EDS) or hypermobility spectrum disorder (HSD) may increase the likelihood of vulvodynia six-fold. Studying vulvodynia in EDS/HSD may help identify causes of vulvodynia and potential treatments. Currently there are no consistently effective treatment methods for vulvodynia. We aim to identify comorbid condition patterns and how they affect a participant’s likelihood of screening positive for vulvodynia. Design: Online survey. Methods: A secondary analysis was conducted using latent class analysis on data from females aged ≥18 years with EDS or HSD ( N = 1,016) who were screened for vulvodynia. Results: Five comorbid condition patterns of 9 indicators were identified. Among the patterns 2 overarching comorbid condition phenotypes were present, 1) non-musculoskeletal phenotype ( n = 185) comprised of mast cell activation disorder, gastrointestinal conditions, and dysautonomia; and 2) pain phenotype ( n = 442) comprised of chronic pain and pelvic instability; 201 participants endorsed both phenotypes. The non-musculoskeletal phenotype incurred the smallest likelihood of screening positive, followed by the pain phenotype. Endorsed both phenotypes resulted in significantly greater likelihood of screening vulvodynia positive ( p < 0.05) compared to one phenotype. Conclusions: Phenotypes may constitute 1) different pathways for developing vulvodynia and/or 2) different subtypes of vulvodynia and/or EDS. We hypothesize that as a person…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.